Selection of Patients With Chronic Inflammatory Rheumatism Requiring Management During the COVID-19 Pandemia
NCT04806867 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 918
Last updated 2021-04-01
Summary
The project proposes to evaluate a strategy for prioritizing teleconsultation for patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemia. This selection will be done through telephone contact by medical students, supervised by residents and rheumatologists on a patient database. The other objectives are to assess the impact of the pandemia on the physical and mental health of patients classified as being at risk
Conditions
- Covid19
- Inflammatory Rheumatism
- Rheumatoid Arthritis
- Spondyloarthritis
- Inflammatory Arthritis
Interventions
- OTHER
-
SePaRIC-Covid19 cohort
All patients with Chronic Inflammatory Rheumatism who were contacted by telephone as part of the innovative organizational strategy and who did not object to the use of their data.
Sponsors & Collaborators
-
University Hospital, Limoges
lead OTHER
Principal Investigators
-
Pascale PV Vergne-Salle, MD-PhD · University Hospital, Limoges
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-01
- Primary Completion
- 2020-07-01
- Completion
- 2020-07-31
Countries
- France
Study Locations
More Related Trials
-
Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
NCT05026892 ·Status: UNKNOWN
-
The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA
NCT04973787 ·Status: UNKNOWN
-
Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor
NCT04530305 ·Status: UNKNOWN
-
SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism
NCT04584541 ·Status: TERMINATED ·Phase: NA
-
Predictive Factors for COVID-19 in Rheumatology
NCT04567576 ·Status: UNKNOWN
-
COVID-19 Vaccination in Patients With Rheumatic Diseases
NCT04845997 ·Status: UNKNOWN
-
Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection
NCT04568421 ·Status: COMPLETED
-
COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL
NCT04542031 ·Status: COMPLETED ·Phase: NA
-
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
NCT05428488 ·Status: RECRUITING ·Phase: PHASE3
-
Longitudinal Follow-up of Patients With Chronic Inflammatory Rheumatisms (CIRs) Vaccinated Against COVID-19 Compared to Patients Refusing Vaccination
NCT04832022 ·Status: COMPLETED
-
Biomedicines and Bacterial Translocation in Spondyloarthritis
NCT05244109 ·Status: UNKNOWN ·Phase: NA
-
IL17 Rate and Spondyloarthritis
NCT05592574 ·Status: RECRUITING
-
Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy
NCT04899154 ·Status: RECRUITING ·Phase: NA
-
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
NCT02451748 ·Status: COMPLETED ·Phase: PHASE4
-
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
NCT01519791 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
NCT01521923 ·Status: COMPLETED ·Phase: PHASE3
-
C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France
NCT02886689 ·Status: COMPLETED
-
Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis
NCT04870203 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
NCT03073109 ·Status: COMPLETED
-
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
NCT03449758 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs
NCT04499001 ·Status: UNKNOWN
-
Study of the Articular Microbiota in Rheumatoid Arthritis.
NCT04056234 ·Status: COMPLETED
-
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
NCT02097524 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
NCT05290363 ·Status: RECRUITING ·Phase: NA
-
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
NCT01034397 ·Status: COMPLETED ·Phase: PHASE4